Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Gross Profit (2020 - 2025)

BridgeBio Pharma's Gross Profit history spans 6 years, with the latest figure at $146.1 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 3746.0% year-over-year to $146.1 million; the TTM value through Dec 2025 reached $481.1 million, up 120.67%, while the annual FY2025 figure was $481.1 million, 120.67% up from the prior year.
  • Gross Profit for Q4 2025 was $146.1 million at BridgeBio Pharma, up from $114.1 million in the prior quarter.
  • Across five years, Gross Profit topped out at $210.5 million in Q1 2024 and bottomed at -$2.4 million in Q4 2021.
  • The 5-year median for Gross Profit is $3.6 million (2023), against an average of $49.1 million.
  • The largest annual shift saw Gross Profit plummeted 98.57% in 2023 before it skyrocketed 17816.77% in 2024.
  • A 5-year view of Gross Profit shows it stood at -$2.4 million in 2021, then surged by 151.36% to $1.2 million in 2022, then dropped by 6.21% to $1.1 million in 2023, then surged by 231.12% to $3.8 million in 2024, then soared by 3746.0% to $146.1 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Gross Profit are $146.1 million (Q4 2025), $114.1 million (Q3 2025), and $106.9 million (Q2 2025).